Whaley Glenn
Known title: Chief Financial OfficerCIK: 0001724623
Whaley Glenn's purchase track record
How the stock did after each of Whaley Glenn's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since May 12, 2022
Stock higher 6 months later
20%
3 months: 80%
Median 6-month return
-44.9%
3 months: +9.4%
Beat the S&P 500
20%
median -51.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/3/2025 | IMUX | $32K | +9.4% | -10.7% | +14.4% |
| 5/15/2023 | IMUX | $9K | +2.8% | -44.9% | +6.7% |
| 11/7/2022 | IMUX | $7K | +82.5% | +25.2% | +8.7% |
| 6/3/2022 | IMUX | $11K | +33.9% | -59.9% | -0.9% |
| 5/12/2022 | IMUX | $15K | -4.5% | -70.7% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IMUX | ▲ Buy | Open Market | 45,000 | $32K | 6/3/2025 | View on chart |
| IMUX | ▲ Buy | Grant | 25,000 | $14K | 5/30/2025 | View on chart |
| IMUX | ▲ Buy | Open Market | 5,000 | $9K | 5/15/2023 | View on chart |
| IMUX | ▲ Buy | Open Market | 5,000 | $7K | 11/7/2022 | View on chart |
| IMUX | ▲ Buy | Open Market | 3,500 | $11K | 6/3/2022 | View on chart |
| IMUX | ▲ Buy | Open Market | 3,000 | $15K | 5/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Immunic Presents Four Abstracts at MSToronto2026
Immunic announced that four of its research abstracts were accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026. This event highlights the company's ongoing scientific activity in its field. The stock is currently trading near its 52-week low, with an RSI of 22.5 indicating oversold conditions.
Immunic Presents Four Abstracts at MSToronto2026. Immunic announced that four of its research abstracts were accepted for presentation at the 10th Joint ACTRIMS-ECTRIMS Meeting, known as MSToronto2026. This event highlights the company's ongoing scientific activity in its field. The stock is currently trading near its 52-week low, with an RSI of 22.5 indicating oversold conditions.